– Mismatch Repair Deficient (dMMR)
Brand Name: Jemperli
Active Ingredient: Dostarlimab
Strength: Jemperli is available in vials containing 500 mg of dostarlimab.
Manufacturer Name: GlaxoSmithKline (GSK)
List of Excipients: : L-histidine, L-histidine hydrochloride monohydrate, polysorbate 80, trehalose dihydrate.
Jemperli is a cutting-edge medical solution developed to address the treatment of mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) endometrial cancer, as well as dMMR solid tumors. With its advanced therapeutic approach, Jemperli offers renewed hope to both patients and healthcare professionals by aiming to enhance outcomes and elevate the quality of life for individuals grappling with these complex conditions.
Special Storage Precautions: Jemperli vials should Store in the refrigerator between 2°C to 8°C (36°F to 46°F). Do not freeze.
· Precision Targeting: Jemperli employs a targeted therapy strategy that focuses on addressing the specific genetic markers associated with mismatch repair deficiency and microsatellite instability-high, providing a tailored and effective treatment avenue.
· Clinical Efficacy: Supported by comprehensive clinical trials, Jemperli demonstrates a compelling level of effectiveness in managing dMMR or MSI-H endometrial cancer and dMMR solid tumors, potentially leading to favorable patient outcomes.
· Innovative Mechanism: Jemperli operates through a novel mechanism of action, leveraging the latest advancements in medical science to disrupt disease progression at the molecular level.
· Personalized Care: Jemperli’s treatment approach is personalized, recognizing the unique genetic makeup of each patient, thereby enabling a more precise and targeted therapeutic intervention.
· Formulation: Injectable solution
· Administration: To be administered exclusively under the supervision of a qualified healthcare professional
· Storage: Store in accordance with recommended temperature and conditions as specified in the product labeling
· Packaging: Presented in user-friendly single-dose vials to facilitate accurate and convenient dosing
Jemperli is intended to be used as directed by a licensed healthcare provider experienced in managing dMMR or MSI-H endometrial cancer and dMMR solid tumors. The determination of appropriate dosage and administration should be tailored to each patient’s unique medical profile and treatment regimen. Regular monitoring and scheduled follow-up appointments are crucial for assessing treatment progress and effectively managing potential side effects.
The information presented herein is intended for educational and informational purposes only. It should not be considered a substitute for professional healthcare advice or recommendations. For personalized guidance and treatment options tailored to your specific medical condition, it is essential to consult a qualified healthcare provider.
ARKON SOLUTIONS are one of the world’s most prestigious and trustworthy distributors of pharmaceutical products and assists in distributing Drugs For Patients, Pharma Companies And CROs and RLD
We provide easy and quick access to anakinra injection at a reasonable cost in India. We offer a quality guarantee and delivery anywhere in the world based on the customer’s needs.
ARKON SOLUTIONS has access to and the capacity to supply Kineret Injection from all over the world.
For more information contact us on , or call us at +912225604238 / +91 7777001263 or Email us to [email protected] to know the anakinra injection price in India. Our friendly staff will happily guide you and answer any general or medical enquiry.
Individuals with a known hypersensitivity or allergic reactions to any components of Jemperli should avoid its use. Patients with certain medical conditions or undergoing specific treatments should consult their healthcare provider regarding the suitability of Jemperli before initiating treatment.
Jemperli should be stored according to the guidelines provided in its product labeling. Generally, it is advisable to store Jemperli within a specific temperature range and suitable conditions. Please refer to the packaging or consult your healthcare provider for precise details on proper storage.
Jemperli has shown promising clinical efficacy in managing mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) endometrial cancer and dMMR solid tumors. Clinical trials have demonstrated positive outcomes, potentially improving disease management and patient well-being. However, individual responses may vary, and the effectiveness of Jemperli should be discussed with a healthcare provider based on your specific medical condition.
Jemperli is administered under the supervision of a qualified healthcare professional, usually as an injectable solution. The appropriate dosage and administration schedule are determined by your healthcare provider, considering factors such as your medical history, overall health, and the nature of your condition. Adhering to your healthcare provider’s instructions for proper administration and dosing is crucial.
Like any medical intervention, Jemperli may have potential side effects. Common side effects may include fatigue, nausea, vomiting, diarrhea, and changes in appetite. Serious or severe side effects are also possible. It is important to promptly inform your healthcare provider of any unusual symptoms or concerns. Your healthcare provider will provide information about potential side effects, monitoring procedures, and steps to manage any adverse reactions that may arise during treatment.